Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Provider Information: PCV13 VIS

Current Edition Date: 10/22/14

These provider guidelines supplement the VIS and summarize relevant ACIP recommendations; include more detailed information about indications, schedules, and precautions; and contain other information giving providers a quick reference to help address common patients' questions.

PCV13 is approved for persons 6 weeks through 17 years age and adults 50 and older.

ACIP Recommendations: Children through 5 Years (71 months)

Routine series at 2, 4, 6, and 12 through 15 months. Minimum intervals:

  • Dose 1 to Dose 2: 4 weeks
  • Dose 2 to Dose 3: 4 weeks
  • Dose 3 to Dose 4: 8 weeks

For children who start late or fall behind, recommendations can be found on CDC's Pediatric Catch-Up Schedule.

ACIP Recommendations: Children 6 through 18 Years

Children 6 through 18 years who have not received PCV13 previously, and are at high risk for invasive pneumococcal disease because of:

  • Anatomic or functional asplenia (including sickle cell disease)
  • Immunocompromising conditions, including HIV infection
  • Cochlear implant
  • CSF leaks

should receive a single dose of PCV13 (regardless of any previous history of PCV7 and/or PPSV23).

ACIP Recommendations: Adults 19 and Older

Adults 19 and older who have not received either PCV or PPSV previously, and are at high risk for invasive pneumococcal disease because of:

  • Anatomic or functional asplenia (including sickle cell disease)
  • Immunocompromising conditions, including HIV infection
  • Cochlear implant
  • CSF leaks

should receive a single dose of PCV13. (This should be followed with a dose of PPSV at least 8 weeks later. Those who have indications for revaccination with PPSV should receive a second dose at least 5 years after the first.)

Adults 19 and older with any of these conditions who have received one or more doses of PPSV previously should receive a single dose of PCV13 at least one year after the last dose of PPSV.

[Note that use of PCV13 for persons 18 through 49 years of age, while recommended by ACIP in these circumstances, is off-label.] Appropriate intervals between doses of PCV and PPSV can be found in PCV MMWR (for children) and PSV MMWR (for adults).

Pneumococcal polysaccharide vaccine (PPSV23) may also be recommended for children 2 years of age and older and adults through age 64 with high-risk health conditions, and routinely for adults 65 and older.

Contraindications and Precautions

PCV13 is contraindicated for people who have had an anaphylactic reaction to a diphtheria-toxoid containing vaccine, because the antigens in PCV13 are conjugated to diphtheria CRM197 protein.

PCV13 is contraindicated for anyone with a history of anaphylactic hypersensitivity to any vaccine component. For a list of PCV13 vaccine contents, see the package insert or the vaccine excipient table [4 pages].

PCV13 packaging does not contain latex.

"The presence of a moderate or severe acute illness with or without a fever is a precaution to administration of all vaccines." (ACIP General Recommendations on Immunization, p.11) (The definition of "moderate or severe acute illness" is left up to the clinical judgment of the provider.)

Top of Page

Many Vaccine Information Statements are available in español and other languages. See http://www.immunize.org/vis.

Hojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite http://www.immunize.org/vis/vis_spanish.asp

Top